In ₹ Crore except Per Share Latest Annual | AARTIDRUGS FY26 | ALIVUS FY24 | AARTIPHARM FY26 | ADVENZYMES FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 20.46× | — | 43.02× | ◆ 20.04× | 31.53× -35% | |
| P/B | 2.57× | — | 3.54× | ◆ 2.01× | 2.77× -7% | |
| EV/EBITDA | 14.74× | — | 22.19× | ◆ 11.83× | 17.01× -13% | |
| Market Cap | ₹3,988 Cr | — | ₹7,516 Cr | ₹3,382 Cr | ₹5,449 Cr -27% | |
| Growth | ||||||
| Revenue CAGR 3Y | -1.89% | — | -2.20% | ◆ 11.32% | 4.56% -141% | |
| Revenue CAGR 5Y | 3.55% | — | — | ◆ 8.24% | 8.24% -57% | |
| Net Income CAGR 3Y | 5.43% | — | -3.35% | ◆ 18.68% | 7.67% -29% | |
| Revenue YoY (latest Q) | 19.01% | — | ◆ 38.74% | 2.08% | 20.41% -7% | |
| Net Income YoY (latest Q) | -7.12% | — | ◆ 53.82% | -4.58% | 24.62% -129% | |
| Profitability | ||||||
| EBITDA Margin | 12.05% | 29.53% | 20.29% | ◆ 30.72% | 29.53% -59% | |
| Net Income Margin | 7.60% | 20.62% | 9.60% | ◆ 23.28% | 20.62% -63% | |
| Return on Common Equity | 12.58% | ◆ 20.19% | 8.13% | 10.02% | 10.02% +26% | |
| Return on Capital Employed | 12.80% | ◆ 25.74% | 10.41% | 10.91% | 10.91% +17% | |
| Return on Assets | 6.92% | ◆ 16.52% | 5.02% | 9.44% | 9.44% -27% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.37× | — | 0.32× | ◆ 0.01× | 0.17× +124% | |
| Interest Coverage | 7.19× | ◆ 401.55× | 5.65× | 71.91× | 71.91× -90% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹2,565 Cr | ₹2,283 Cr | ₹1,819 Cr | ₹746 Cr | ₹1,819 Cr +41% | |
| Net Income | ₹195 Cr | ₹471 Cr | ₹175 Cr | ₹174 Cr | ₹175 Cr +12% | |
| Total Assets | ₹2,815 Cr | ₹2,850 Cr | ₹3,482 Cr | ₹1,839 Cr | ₹2,850 Cr -1% | |
| EPS | ₹21.36 | — | ₹19.27 | ₹15.08 | ₹17.18 +24% | |
| Book Value per Share | ₹169.74 | — | ₹234.35 | ₹150.38 | ₹192.37 -12% | |